Literature DB >> 1830897

The effect of a dihydropyridine calcium antagonist (isradipine) on selective neuronal necrosis.

S Ohta1, M L Smith, B K Siesjö.   

Abstract

The experiments were designed to test the possibility that calcium influx into neurons via voltage sensitive calcium channels (VSCCs) contribute to brain damage in two conditions in which any amelioration of neuronal necrosis may be assumed not to occur through an improvement of blood flow, viz., hypoglycemic coma and brief transient ischemia. Hypoglycemic coma is thought to lead to neuronal necrosis by release of glutamate and cellular influx of calcium during the insult, while damage due to brief transient ischemia may, at least in part, result from increased calcium cycling across cell membranes in the postinsult period. The insults were delivered to anesthetized rats, and the localization and density of neuronal necrosis were evaluated by histopathology following 1 week of recovery. One dihydropyridine calcium antagonist (isradipine), given in doses which have been reported to ameliorate ischemic damage due to stroke, failed to reduce damage incurred by 30 min of hypoglycemic coma, or 15 min of transient forebrain ischemia. Provided that it can be assumed that isradipine in the doses employed reduced calcium influx via VSCCs, the results support the notion that calcium influx through VSCCs plays only a minor pathogenetic role in global/forebrain ischemia or in hypoglycemia, and they suggest that the effect of blockers of VSCCs in stroke, if any, is due to both blockade of VSCCs and increase in blood flow.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1830897     DOI: 10.1016/0022-510x(91)90293-g

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

Review 1.  Calcium, energy metabolism and the development of selective neuronal loss following short-term cerebral ischemia.

Authors:  N R Sims
Journal:  Metab Brain Dis       Date:  1995-09       Impact factor: 3.584

2.  125I-Labelled mapacalcine: a specific tool for a pharmacological approach to a receptor associated with a new calcium channel on mouse intestinal membranes.

Authors:  P Vidalenc; J L Morel; J Mironneau; M Hugues
Journal:  Biochem J       Date:  1998-04-01       Impact factor: 3.857

3.  A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia.

Authors:  K Valentino; R Newcomb; T Gadbois; T Singh; S Bowersox; S Bitner; A Justice; D Yamashiro; B B Hoffman; R Ciaranello
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

Review 4.  Control of intracellular calcium signaling as a neuroprotective strategy.

Authors:  R Scott Duncan; Daryl L Goad; Michael A Grillo; Simon Kaja; Andrew J Payne; Peter Koulen
Journal:  Molecules       Date:  2010-03-03       Impact factor: 4.411

5.  Mediation of the neuroprotective action of R-phenylisopropyl-adenosine through a centrally located adenosine A1 receptor.

Authors:  D G MacGregor; W J Miller; T W Stone
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

6.  Hypoglycaemic brain damage: effect of a dihydropyridine calcium channel antagonist in rats.

Authors:  R N Auer; L G Anderson
Journal:  Diabetologia       Date:  1996-02       Impact factor: 10.122

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.